Results 201 to 210 of about 8,164,322 (359)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Trends in gabapentinoid prescribing: A nationwide Danish drug utilization study. [PDF]

Br J Clin Pharmacol
Pottegård A, Rasmussen L, Olesen M, Skov Sørensen AM, Ennis ZN, Kane J, Baxter S, Hicks B.   +7 more
europepmc   +1 more source

A PRESCRIPTION AUDIT AND ASSESSMENT OF DRUG UTILIZATION PATTERN IN A TERTIARY CARE TEACHING AND REFERRAL HOSPITAL IN UTTAR PRADESH, INDIA

, 2019
Surabhi Arora, Afroz Abidi, Dilshad Ali Rizvi   +2 more
openalex   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Use of oral fluoroquinolones in France between 2014 and 2023: a nationwide drug utilization study. [PDF]

JAC Antimicrob Resist
Saade D, Jabagi MJ, Bertrand M, Hider-Mlynarz K, Grimaldi L, Zureik M.   +5 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Utilização de antimicrobianos em uma população urbana

Revista de Saúde Pública
OBJETIVO: A emergência de cepas microbianas com crescentes níveis de resistência aos antimicrobianos tem sido objeto de preocupação em todo o mundo. Entre as causas apontadas para o fenômeno, está o uso abusivo e indiscriminado de drogas antimicrobianas.
Laura S Berquó, Aluísio J D Barros, Rosângela C Lima, Andréa D Bertoldi   +3 more
doaj  

Drug utilization in geriatric psychiatric patients in the emergency department-a cohort study under real-world conditions. [PDF]

Ther Adv Psychopharmacol
Schulze Westhoff M, Bannasch S, Heck J, Bleich S, Schröder S, Groh A.   +5 more
europepmc   +1 more source

A Drug Utilization Study of Anti-glaucoma Drugs in a Tertiary Care Hospital. [PDF]

Cureus, 2023
Meesala A, Tripathy R, Chaudhury HC, Sahoo JP.   +3 more
europepmc   +1 more source

Utilization of psychotropic drugs prescribed to persons with and without HIV infection: a Danish nationwide population‐based cohort study [PDF]

, 2014
Line Dahlerup Rasmussen, Dorrit Obel, Gitte Kronborg, Carsten Schade Larsen, C Pedersen, Jan Gerstoft, Niels Obel   +6 more
openalex   +1 more source